Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab

设为首页

收藏本站

网站地图 | English | 公务邮箱

远程访问

NSTL服务站

Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab

详细信息查看全文

作者：Philippe Bégin (1) Tina Dominguez (1) Shruti P Wilson (1) Liane Bacal (1) Anjuli Mehrotra (1) Bethany Kausch (1) Anthony Trela (1) Morvarid Tavassoli (1) Elisabeth Hoyte (1) Gerri O’Riordan (1) Alanna Blakemore (1) Scott Seki (1) Robert G Hamilton (2) Kari C Nadeau (1)
关键词：Food allergy ; Oral immunotherapy (OIT) ; Specific Oral Tolerance Induction (SOTI) ; Multiple food allergy ; Safety ; Efficacy ; Omalizumab ; Desensitization
刊名：Allergy, Asthma & Clinical Immunology
出版年：2014
出版时间：December 2014
年：2014
卷：10
期：1
全文大小：445 KB
参考文献：1. McGowan EC, Keet CA: Prevalence of self-reported food allergy in the National Health and Nutrition Examination Survey (NHANES) 2007-010. / J Allergy Clin Immunol 2013,132(5):1216-. blank" title="It opens in new window">CrossRef 2. Soller L, Ben-Shoshan M, Harrington DW, Fragapane J, Joseph L, St Pierre Y, / et al.: Overall prevalence of self-reported food allergy in Canada. / J Allergy Clin Immunol 2012,130(4):986-88. blank" title="It opens in new window">CrossRef 3. Gupta RS, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, / et al.: The prevalence, severity, and distribution of childhood food allergy in the United States. / Pediatrics 2011,128(1):e9-e17. blank" title="It opens in new window">CrossRef 4. Gupta R, Holdford D, Bilaver L, Dyer A, Holl JL, Meltzer D: The economic impact of childhood food allergy in the United States. / JAMA Pediatr 2013.,137(11): 5. Sicherer SH, Noone SA, Munoz-Furlong A: The impact of childhood food allergy on quality of life. / Ann Allergy Asthma Immunol 2001,87(6):461-64. blank" title="It opens in new window">CrossRef 6. Christie L, Hine RJ, Parker JG, Burks W: Food allergies in children affect nutrient intake and growth. / J Am Diet Assoc 2002,102(11):1648-651. blank" title="It opens in new window">CrossRef 7. Savage JH, Matsui EC, Skripak JM, Wood RA: The natural history of egg allergy. / J Allergy Clin Immunol 2007,120(6):1413-417. blank" title="It opens in new window">CrossRef 8. Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, / et al.: A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow’s milk allergy. / J Allergy Clin Immunol 2008,122(6):1154-160. blank" title="It opens in new window">CrossRef 9. Pajno GB, Caminiti L, Ruggeri P, De Luca R, Vita D, La Rosa M, / et al.: Oral immunotherapy for cow’s milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. / Ann Allergy Asthma Immunol 2010,105(5):376-81. blank" title="It opens in new window">CrossRef 10. de Boissieu D, Dupont C: Sublingual immunotherapy for cow’s milk protein allergy: a preliminary report. / Allergy 2006,61(10):1238-239. blank" title="It opens in new window">CrossRef 11. Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A, Ronfani L, / et al.: Specific oral tolerance induction in children with very severe cow’s milk-induced reactions. / J Allergy Clin Immunol 2008,121(2):343-47. blank" title="It opens in new window">CrossRef 12. Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG: A protocol for oral desensitization in children with IgE-mediated cow’s milk allergy. / Allergy 2004,59(9):980-87. blank" title="It opens in new window">CrossRef 13. Fisher HR, du Toit G, Lack G: Specific oral tolerance induction in food allergic children: is oral desensitisation more effective than allergen avoidance?: a meta-analysis of published RCTs. / Arch Dis Child 2011,96(3):259-64. blank" title="It opens in new window">CrossRef 14. Staden U, Rolinck-Werninghaus C, Brewe F, Wahn U, Niggemann B, Beyer K: Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. / Allergy 2007,62(11):1261-269. blank" title="It opens in new window">CrossRef 15. Dupont C, Kalach N, Soulaines P, Legoue-Morillon S, Piloquet H, Benhamou PH: Cow’s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. / J Allergy Clin Immunol 2010,125(5):1165-167. blank" title="It opens in new window">CrossRef 16. Dello Iacono I, Tripodi S, Calvani M, Panetta V, Verga MC, Miceli SS: Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: a randomized controlled trial. / Pediatr Allergy Immunol 2013,24(1):66-4. blank" title="It opens in new window">CrossRef 17. Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, / et al.: Oral immunotherapy for treatment of egg allergy in children. / N Engl J Med 2012,367(3):233-43. blank" title="It opens in new window">CrossRef 18. Garcia Rodriguez R, Urra JM, Feo-Brito F, Galindo PA, Borja J, Gomez E, / et al.: Oral rush desensitization to egg: efficacy and safety. / Clin Exp Allergy 2011,41(9):1289-296. blank" title="It opens in new window">CrossRef 19. Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, / et al.: Safety of a peanut oral immunotherapy protocol in children with peanut allergy. / J Allergy Clin Immunol 2009,124(2):286-91. e1- blank" title="It opens in new window">CrossRef 20. Blumchen K, Ulbricht H, Staden U, Dobberstein K, Beschorner J, de Oliveira LC, / et al.: Oral peanut immunotherapy in children with peanut anaphylaxis. / J Allergy Clin Immunol 2010,126(1):83-1. e1 blank" title="It opens in new window">CrossRef 21. Clark AT, Islam S, King Y, Deighton J, Anagnostou K, Ewan PW: Successful oral tolerance induction in severe peanut allergy. / Allergy 2009,64(8):1218-220. blank" title="It opens in new window">CrossRef 22. Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, / et al.: Clinical efficacy and immune regulation with peanut oral immunotherapy. / J Allergy Clin Immunol 2009,124(2):292-00. e1-7 blank" title="It opens in new window">CrossRef 23. Yu GP, Weldon B, Neale-May S, Nadeau KC: The safety of peanut oral immunotherapy in peanut-allergic subjects in a single-center trial. / Int Arch Allergy Immunol 2012,159(2):179-82. blank" title="It opens in new window">CrossRef 24. Fleischer DM, Burks AW, Vickery BP, Scurlock AM, Wood RA, Jones SM, / et al.: Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. / J Allergy Clin Immunol 2013,131(1):119-27. e1- blank" title="It opens in new window">CrossRef 25. Enrique E, Pineda F, Malek T, Bartra J, Basagana M, Tella R, / et al.: Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. / J Allergy Clin Immunol 2005,116(5):1073-079. blank" title="It opens in new window">CrossRef 26. Gomez E, Mayorga C, Gomez F, Blazquez AB, Diaz-Perales A, Blanca M, / et al.: Food allergy: management, diagnosis and treatment strategies. / Immunotherapy 2013,5(7):755-68. blank" title="It opens in new window">CrossRef 27. Sabato V, Faber M, Van Gasse A, Hagendorens MM, Leysen J, Bridts CH, / et al.: State of the art and perspectives in food allergy (part II): therapy. / Curr Pharm Des 2013. EPub May 17 2013 28. Nadeau KC, Kohli A, Iyengar S, DeKruyff RH, Umetsu DT: Oral immunotherapy and anti-IgE antibody-adjunctive treatment for food allergy. / Immunol Allergy Clin North Am 2012,32(1):111-33. blank" title="It opens in new window">CrossRef 29. Yang YH, Chiang BL: Novel approaches to food allergy. / Clin Rev Allergy Immunol 2013. EPub Jan 18 2013 30. Khoriaty E, Umetsu DT: Oral immunotherapy for food allergy: towards a new horizon. / Allergy Asthma Immunol Res 2013,5(1):3-5. blank" title="It opens in new window">CrossRef 31. Kim EH, Burks W: Managing food allergy in childhood. / Curr Opin Pediatr 2012,24(5):615-20. b013e32835741e3" target="_blank" title="It opens in new window">CrossRef 32. Nowak-Wegrzyn A, Sampson HA: Future therapies for food allergies. / J Allergy Clin Immunol 2011,127(3):558-73. quiz 74- blank" title="It opens in new window">CrossRef 33. Virkud YV, Vickery BP: Advances in immunotherapy for food allergy. / Discov Med 2012,14(76):159-65. 34. Nurmatov U, Venderbosch I, Devereux G, Simons FE, Sheikh A: Allergen-specific oral immunotherapy for peanut allergy. / Cochrane Database Syst Rev 2012., 9: CD009014 35. Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S, / et al.: The safety and efficacy of sublingual and oral immunotherapy for milk allergy. / J Allergy Clin Immunol 2012,129(2):448-55. e1- blank" title="It opens in new window">CrossRef 36. Bégin P, Wintheroth L, Dominguez T, Wilson SP, Bacal L, Mehrotra A, / et al.: Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. / Allergy Asthma Clin Immunol 2014,10(1):1. blank" title="It opens in new window">CrossRef 37. Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH, / et al.: Effect of anti-IgE therapy in patients with peanut allergy. / N Engl J Med 2003,348(11):986-93. blank" title="It opens in new window">CrossRef 38. Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM, / et al.: A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. / J Allergy Clin Immunol 2011,127(5):1309-310. e1 blank" title="It opens in new window">CrossRef 39. Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, / et al.: Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. / Int Arch Allergy Immunol 2013, 162:89-3. blank" title="It opens in new window">CrossRef 40. Bedoret D, Singh AK, Shaw V, Hoyte EG, Hamilton R, DeKruyff RH, / et al.: Changes in antigen-specific T-cell number and function during oral desensitization in cow’s milk allergy enabled with omalizumab. / Mucosal Immunol 2012,5(3):267-76. blank" title="It opens in new window">CrossRef 41. Savage JH, Courneya JP, Sterba PM, Macglashan DW, Saini SS, Wood RA: Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. / J Allergy Clin Immunol 2012,130(5):1123-129. e2 blank" title="It opens in new window">CrossRef 42. MacGlashan DW Jr, Savage JH, Wood RA, Saini SS: Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors. / J Allergy Clin Immunol 2012,130(5):1130-135. e5 blank" title="It opens in new window">CrossRef 43. Babu KS, Polosa R, Morjaria JB: Anti-IgE–emerging opportunities for Omalizumab. / Expert Opin Biol Ther 2013,13(5):765-77. blank" title="It opens in new window">CrossRef 44. Lieberman JA, Chehade M: Use of omalizumab in the treatment of food allergy and anaphylaxis. / Curr Allergy Asthma Rep 2013,13(1):78-4. blank" title="It opens in new window">CrossRef 45. Patil SP, Wang J, Song Y, Noone S, Yang N, Wallenstein S, / et al.: Clinical safety of food allergy herbal formula-2 (FAHF-2) and inhibitory effect on basophils from patients with Food allergy: extended phase I study. / J Allergy Clin Immunol 2011,128(6):1259-265. e2 blank" title="It opens in new window">CrossRef 46. Gernez Y, Tirouvanziam R, Yu G, Ghosn EE, Reshamwala N, Nguyen T, / et al.: Basophil CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in subjects with nut allergy. / Int Arch Allergy Immunol 2011,154(4):318-27. blank" title="It opens in new window">CrossRef 47. Yu GP, Tuano KS, Hamilton RG, Nadeau KC: Omalizumab in peanut-allergic patients reduces free IgE anti-peanut and skin prick test to peanut. / J Allergy Clin Immunol 2010,125(2 Supp 1):AB22. 48. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, / et al.: Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. / J Allergy Clin Immunol 2006,117(1):134-40. blank" title="It opens in new window">CrossRef 49. Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT: Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. / J Allergy Clin Immunol 2011,127(6):1622-624. blank" title="It opens in new window">CrossRef 50. Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, / et al.: Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. / J Allergy Clin Immunol 2007,120(3):688-95. blank" title="It opens in new window">CrossRef 51. Parks KW, Casale TB: Anti-immunoglobulin E monoclonal antibody administered with immunotherapy. / Allergy Asthma Proc 2006,27(2 Suppl 1):S33-S36. 52. Schneider LC, Rachid R, Lebovidge J, Blood E, Mittal M, Umetsu DT: A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. / J Allergy Clin Immunol 2013,132(6):1368-374. blank" title="It opens in new window">CrossRef 53. Bock SA, Sampson HA, Atkins FM, Zeiger RS, Lehrer S, Sachs M, / et al.: Double-blind, placebo-controlled food challenge (DBPCFC) as an office procedure: a manual. / J Allergy Clin Immunol 1988,82(6):986-97. blank" title="It opens in new window">CrossRef 54. Wang J, Visness CM, Sampson HA: Food allergen sensitization in inner-city children with asthma. / J Allergy Clin Immunol 2005,115(5):1076-080. blank" title="It opens in new window">CrossRef 55. Wang J: Management of the patient with multiple food allergies. / Curr Allergy Asthma Rep 2010,10(4):271-77. blank" title="It opens in new window">CrossRef 56. Park JH, Ahn SS, Sicherer SH: Prevalence of allergy to multiple versus single foods in a pediatric food allergy referral practice. / J Allergy Clin Immunol 2010, 125:AB216. blank" title="It opens in new window">CrossRef 57. Food Allergy in Children and Young People: / Diagnosis and Assessment of Food Allergy in Children and Young People in Primary Care and Community Settings. London: National Institute for Health and Clinical Excellence: Guidance; 2011. 58. Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, / et al.: A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. / J Allergy Clin Immunol 2011,127(3):654-60. blank" title="It opens in new window">CrossRef
作者单位：Philippe Bégin (1) Tina Dominguez (1) Shruti P Wilson (1) Liane Bacal (1) Anjuli Mehrotra (1) Bethany Kausch (1) Anthony Trela (1) Morvarid Tavassoli (1) Elisabeth Hoyte (1) Gerri O’Riordan (1) Alanna Blakemore (1) Scott Seki (1) Robert G Hamilton (2) Kari C Nadeau (1) 1. Allergy, Immunology, and Rheumatology Division, Stanford University, 269 Campus Drive, CCSR3215c, Stanford, CA, 94305, USA 2. Dermatology, Allergy and Clinical Immunology Reference Laboratory, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
ISSN：1710-1492

文摘

Background Up to 30% of patients with food allergies have clinical reactivity to more than one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under investigation. Pilot data have shown that omalizumab may hasten the ability to tolerate over 4?g of food allergen protein. Objective To evaluate the safety and dose tolerability of a Phase 1 Single Site OIT protocol using omalizumab to allow for a faster and safe desensitization to multiple foods simultaneously. Methods Participants with multiple food allergies received OIT for up to 5 allergens simultaneously with omalizumab (rush mOIT). Omalizumab was administered for 8 weeks prior to and 8 weeks following the initiation of a rush mOIT schedule. Home reactions were recorded with diaries. Results Twenty-five (25) participants were enrolled in the protocol (median age 7 years). For each included food, participants had failed an initial double-blind placebo-controlled food challenge at a protein dose of 100?mg or less. After pre-treatment with omalizumab, 19 participants tolerated all 6 steps of the initial escalation day (up to 1250?mg of combined food proteins), requiring minimal or no rescue therapy. The remaining 6 were started on their highest tolerated dose as their initial daily home doses. Participants reported 401 reactions per 7,530 home doses (5.3%) with a median of 3.2 reactions per 100 doses. Ninety-four percent (94%) of reactions were mild. There was one severe reaction. Participants reached their maintenance dose of 4,000?mg protein per allergen at a median of 18 weeks. Conclusion These phase 1 data demonstrate that rush OIT to multiple foods with 16 weeks of treatment with omalizumab could allow for a fast desensitization in subjects with multiple food allergies. Phase 2 randomized controlled trials are needed to better define safety and efficacy parameters of multi OIT experimental treatments with and without omalizumab.

地址：北京市海淀区学院路29号邮编：100083

电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700